Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

Coletrain02 Apr. 1 at 5:44 PM

$ACRV

0 · Reply

Dani_G_German Apr. 1 at 2:16 PM

$ACRV see you guys back above 2

1 · Reply

Dou_said_it Mar. 30 at 9:17 AM

$ACRV The market should know how ACRV will finance the phase 3…( Partnership or Dillution)… The price will change depending on that

1 · Reply

CyberCuba Mar. 29 at 5:41 PM

$ACRV ACRV investigators need to talk to IBRX and see if NK cells will augment (improve more than 55%) ACRV therapy trial response to serous carcinoma patients. (full disclosure: I own both companies' shares), If so, shares of both companies will surge.

0 · Reply

Dylberts Mar. 27 at 6:06 PM

$ACRV is no exception, the whole damn market is simply bleeding right now except for $USO unfortunate times we're in. Great entry opportunities for those ready though

0 · Reply

Hearts_And_Pikes Mar. 27 at 4:38 PM

$ACRV Sell (your shares to me) the news.

0 · Reply

PreGigs Mar. 27 at 2:50 PM

$ACRV I think this is more just the whole market crashing - I've had this since 1.10$ so we'll se what happens

1 · Reply

Dou_said_it Mar. 27 at 2:11 PM

$ACRV Ouch…

0 · Reply

open_outcry Mar. 27 at 12:50 AM

$ACRV how far will they let it fall? sub- brings its own set of compliance issues and greatly increases changes of a reverse split

1 · Reply

Glorioso2022 Mar. 26 at 7:26 PM

$ACRV fuckers? Look... soon 0,10.🖕🖕🖕🖕🖕

0 · Reply

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 17, 2026, 5:54 PM EDT - 19 days ago

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Feb 18, 2026, 8:00 AM EST - 6 weeks ago

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Jan 23, 2026, 8:11 AM EST - 2 months ago

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Jan 8, 2026, 2:02 PM EST - 3 months ago

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Jan 8, 2026, 7:30 AM EST - 3 months ago

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Jan 6, 2026, 7:30 AM EST - 3 months ago

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 3 months ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Nov 13, 2025, 4:10 PM EST - 5 months ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 22, 2025, 4:15 PM EDT - 5 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 1, 2025, 4:30 PM EDT - 6 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:15 PM EDT - 8 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 11 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 1 year ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 1 year ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 1 year ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 2 years ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 2 years ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 2 years ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 2 years ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 3 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Coletrain02 Apr. 1 at 5:44 PM

$ACRV

0 · Reply

Dani_G_German Apr. 1 at 2:16 PM

$ACRV see you guys back above 2

1 · Reply

Dou_said_it Mar. 30 at 9:17 AM

$ACRV The market should know how ACRV will finance the phase 3…( Partnership or Dillution)… The price will change depending on that

1 · Reply

CyberCuba Mar. 29 at 5:41 PM

0 · Reply

Dylberts Mar. 27 at 6:06 PM

$ACRV is no exception, the whole damn market is simply bleeding right now except for $USO unfortunate times we're in. Great entry opportunities for those ready though

0 · Reply

Hearts_And_Pikes Mar. 27 at 4:38 PM

$ACRV Sell (your shares to me) the news.

0 · Reply

PreGigs Mar. 27 at 2:50 PM

$ACRV I think this is more just the whole market crashing - I've had this since 1.10$ so we'll se what happens

1 · Reply

Dou_said_it Mar. 27 at 2:11 PM

$ACRV Ouch…

0 · Reply

open_outcry Mar. 27 at 12:50 AM

$ACRV how far will they let it fall? sub- brings its own set of compliance issues and greatly increases changes of a reverse split

1 · Reply

Glorioso2022 Mar. 26 at 7:26 PM

$ACRV fuckers? Look... soon 0,10.🖕🖕🖕🖕🖕

0 · Reply

guidoschini Mar. 25 at 6:23 PM

$ACRV Pumpers where are you?

1 · Reply

Winwinwin100 Mar. 24 at 4:40 PM

$ACRV rubbish

0 · Reply

R0MER0 Mar. 24 at 2:05 AM

$ACRV

2 · Reply

MrTicker Mar. 23 at 8:29 PM

$ACRV Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. 10K WIZARD 3:28 PM ET 3/23/2026 http://archive.fast-edgar.com/20260323/A8V2U22CZ222S2Z2222U22ZHR9MREH225282 Filed on: March 23, 2026

0 · Reply

guidoschini Mar. 23 at 7:59 PM

$ACRV It always goes down

0 · Reply

guidoschini Mar. 20 at 10:12 PM

$ACRV Down

0 · Reply

Trinity031983 Mar. 20 at 4:03 PM

$ACRV

0 · Reply

nmarrone2207 Mar. 19 at 9:16 PM

$ACRV Golden cross tomorrow and will bust through the 200 day MA... LFG!

0 · Reply

StockProfitClub Mar. 19 at 7:24 PM

$ACRV https://www.stockprofitclub.com/articles/essential-financial-ratios-for-pharma-stocks

0 · Reply

Trinity031983 Mar. 19 at 5:42 PM

$ACRV

0 · Reply

Trinity031983 Mar. 19 at 5:41 PM

$ACRV

0 · Reply

MrTicker Mar. 19 at 11:32 AM

$ACRV Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate BENZINGA 6:23 AM ET 3/19/2026 Acrivon Therapeutics (ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share from the same period last year.

0 · Reply

Market Cap	58.89M
Revenue (ttm)	0.00
Net Income (ttm)	-77.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	393,300
Avg Vol	803,350
Day's Range	N/A - N/A
Shares Out	38.74M
Stochastic %K	60%
Beta	1.72
Analysts	Strong Sell
Price Target	$11.50